– CANADA, Toronto – BenchSci, a world leader in AI solutions for preclinical research and drug discovery, announced the appointment of Dr. Mikael Dolsten (M.D., Ph.D.) to its board of directors.
About Dr. Mikael Dolsten
Dr. Mikael Dolsten retired from Pfizer Inc., brings over three decades of extensive leadership and scientific expertise. During his 16-year tenure as CSO and President of Pfizer Research & Development, he oversaw the regulatory approval of more than 36 medicines and vaccines. His efforts spearheaded advancements in drug discovery, with over 150 drug candidates progressing to clinical studies, and he played a vital role in the company’s global response to the COVID-19 pandemic.
His leadership experience spans some of the world’s largest pharmaceutical organizations, including Wyeth Research, Boehringer Ingelheim, AstraZeneca, and Pharmacia. His remarkable career has been marked by contributions to approximately 50 drug and vaccine approvals, and through his VC experience, he’s been involved in corporate transactions exceeding $100 billion in value.
Beyond his executive leadership roles, Dr. Mikael Dolsten has held influential positions on several public and private boards, including Agilent Technologies, Rocket Pharmaceuticals, Orbis Medicine, and Arbor Biotechnologies. Additionally, he serves as an investment advisor to leading organizations such as Blackstone Life Sciences, Google’s GV, and Bain & Company. His advisory roles extend to public health initiatives, where he has collaborated with U.S. and U.K. governments and served organizations like the Scripps Research Institute and the Foundation for the NIH.
About BenchSci
BenchSci is a world leader in AI solutions for drug discovery on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a Deloitte Technology Fast 50™ and Fast 500™ winner and a certified Great Place to Work.
Since its inception, BenchSci has pioneered the application of AI through its platform, ASCEND, which acts as a scalable AI assistant for preclinical scientists. ASCEND transforms preclinical R&D by decoding biomedical research, multi-omics data and integrating it with proprietary customer data. This creates an unbiased map of the underlying disease biology, empowering scientists to discover novel insights and accelerate R&D. ASCEND supports core functions from target identification to experimental design, validation, and translational workflows, increasing productivity. By streamlining preclinical research and prioritizing the most promising experiments, ASCEND accelerates the path to life-saving treatments.
BenchSci remains steadfast in its mission to solve the number one reason drug discovery projects fail—getting the biology wrong.
For more information, https://www.benchsci.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.